We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Office of Surveillance and Epidemiology Outlines Plans for 2021
Office of Surveillance and Epidemiology Outlines Plans for 2021
The Center for Drug Evaluation and Research’s Office of Surveillance and Epidemiology (OSE) said it aims to prioritize Risk Evaluation and Mitigation Strategy (REMS) assessments and the use of new technologies to evaluate adverse event reports, among other priority activities highlighted in its first-ever annual report released yesterday.